An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD
Author:
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference15 articles.
1. The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
2. Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases
3. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials;Franciosi;Lancet Respir Med,2013
4. Singh D , Abbott-Banner K , Bengtsson T , et al. The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD. Eur Respir J 2018.
5. The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review;Andreeva-Gateva;Postgrad Med,2016
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials;Immunotherapy;2023-12
2. Phosphodiesterase inhibitors and lung diseases;Advances in Pharmacology;2023
3. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review;International Journal of Chronic Obstructive Pulmonary Disease;2021-08
4. Role of β2-adrenergic receptors in chronic obstructive pulmonary disease;Life Sciences;2021-01
5. Nebulized Therapies in COPD: Past, Present, and the Future;International Journal of Chronic Obstructive Pulmonary Disease;2020-07
Nebulized Therapies in COPD: Past, Present, and the Future
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3